KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Operating Expenses (2018 - 2025)

Adaptive Biotechnologies' Operating Expenses history spans 8 years, with the latest figure at $84.5 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 3.88% year-over-year to $84.5 million; the TTM value through Dec 2025 reached $334.1 million, down 2.17%, while the annual FY2025 figure was $334.1 million, 2.17% down from the prior year.
  • Operating Expenses for Q4 2025 was $84.5 million at Adaptive Biotechnologies, up from $83.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $116.9 million in Q4 2023 and bottomed at $79.1 million in Q3 2024.
  • The 5-year median for Operating Expenses is $90.6 million (2024), against an average of $91.1 million.
  • The largest annual shift saw Operating Expenses soared 52.46% in 2021 before it plummeted 30.43% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $99.5 million in 2021, then dropped by 5.17% to $94.4 million in 2022, then rose by 23.8% to $116.9 million in 2023, then tumbled by 30.43% to $81.3 million in 2024, then increased by 3.88% to $84.5 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Operating Expenses are $84.5 million (Q4 2025), $83.7 million (Q3 2025), and $83.9 million (Q2 2025).